Preemptive Pharmacogenomics Testing Among Geriatric Patients

Not Applicable

• Conditions: Pharmacogenomic Testing; Polypharmacy
• Interventions: Genetic: Multigene pharmacogenomics test

• Registration Number: NCT05091879
• Lead Sponsor: Geisinger Clinic

Brief Summary

The primary goal of this study is to conduct pharmacogenomics testing (a type of DNA test) within an aging population and measure the impact of this test on medication selection, dosing, healthcare utilization, and costs of care.

Detailed Description

Pharmacogenomics is the study of how a patient's unique DNA may interact with medications that the patient currently takes or may take in the future. DNA may change how a patient reacts to a medication, such as changing how well it works or the side effects. Knowing a patient's DNA profile may help healthcare professionals select the best medication treatment plan to use. This could include selecting the best medication to give or the medication strength that will work best for the patient. Currently, there is no standard that helps healthcare professionals decide to order a pharmacogenomics test that includes multiple genes. The investigators of this study think that having these DNA results in the medical record for participants who are at least 65 years old and are taking 5 or more medications will result in better health since healthcare professionals may use these results for treatment planning. Knowing if this is true will help healthcare professionals decide if ordering this test will improve patient health.

This study seeks to recruit participants for a pharmacogenomic study who visit at Geisinger 65 Forward locations. Patients who meet the study requirements and consent to be enrolled in this study will be randomly put into a group that receives this pharmacogenomics test or a group that does not receive it. There is a 50% chance of being put in the group that receives this pharmacogenomics test. The investigators will follow all patients enrolled in this study as they visit with their healthcare providers in the future. Geisinger healthcare professionals will have access to the results of this test in the medical record.

Study Timeline

• Study First Submitted: 2021-09-27
• Study First Submitted QC: 2021-10-12
• Study First Posted: 2021-10-25
• Study Start: 2023-03-28
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-25
• Last Update Posted: 2024-04-26
• Primary Completion: 2025-01
• Study Completion: 2025-05

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• Follows at a Geisinger 65 Forward clinic location
• Active prescriptions for 5 or more medications

Read More

Exclusion Criteria

• Liver transplantation
• Allogenic hematopoetic stem cell transplantation
• Previously enrolled in the Electronic Medical Records and Genomics (eMERGE) pharmacogenomics cohort

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pharmacogenomics Testing	Multigene pharmacogenomics test	Patients in the experimental arm will be ordered a multigene pharmacogenomics test. This DNA test requires a blood draw, with the results expected to be reported in the medical record approximately 7 to 14 calendar days after the blood draw. These results will be made available to Geisinger healthcare professionals that have a treatment relationship with study participants.

Primary Outcome Measures

Name	Time	Method
Number of pharmacogenomic results returned in patients' health records	Date of blood draw to test results reported in medical record, up to 1 month	The primary objective will be assessed by comparing the total number of patients with returned results in the electronic health record (EHR) with the total number of tested patients.

Secondary Outcome Measures

Name	Time	Method
Number of hospitalizations	Date of test results reported to end of study, up to 5 years	The number of hospitalizations patients encounter after receiving pharmacogenomics results
Pharmacy costs of care	Date of test results reported to end of study, up to 5 years	Measure of the costs of all pharmacy services (e.g. medications, consults, etc.).
Composite of changes to medication therapy	Date of test results reported to end of study, up to 5 years	The number of medication changes (e.g. dose or agent change) that healthcare professionals initiate due to pharmacogenomics return of results.
Number of ambulatory visits	Date of test results reported to end of study, up to 5 years	The number of outpatient clinic visits patients encounter.
Costs of clinical care	Date of test results reported to end of study, up to 5 years	The total healthcare costs of patients.
Medical costs of care	Date of test results reported to end of study, up to 5 years	Measure of the costs of medical care (e.g. hospitalizations, outpatient visits, etc.), excluding pharmacy services.

Trial Locations

Locations (1)

Geisinger; 🇺🇸 Danville, Pennsylvania, United States